You are here » Home » Companies » Company Overview » Advanced Micronic Devices Ltd

Advanced Micronic Devices Ltd.

BSE: 517552	Sector: Health care
NSE: N.A.	ISIN Code: INE903C01013

BSE 00:00 | 10 Dec

Advanced Micronic Devices Ltd

NSE 05:30 | 01 Jan

Advanced Micronic Devices Ltd

Add to Watchlist | Add to Portfolio

OPEN	9.55
PREVIOUS CLOSE	9.55
VOLUME	5
52-Week high	9.55
52-Week low	0.00
P/E
Mkt Cap.(Rs cr)	5
Buy Price	0.00
Buy Qty	0.00
Sell Price	0.00
Sell Qty	0.00

OPEN	9.55
CLOSE	9.55
VOLUME	5
52-Week high	9.55
52-Week low	0.00
P/E
Mkt Cap.(Rs cr)	5
Buy Price	0.00
Buy Qty	0.00
Sell Price	0.00
Sell Qty	0.00

Advanced Micronic Devices Ltd. (ADVANCEDMICRON) - News Sector

Lupin slips 9%, hits 2-year low on disappointing March quarter results

9.39 am | 19 May 2022 | Business Standard

Lupin's performance was skewed on revenues front amid US and India posting lower than expected sales while RoW and South Africa saw better than antici...
How Prathap Chandra Reddy propelled Apollo Hospitals into a new orbit

9.35 pm | 18 May 2022 | Business Standard

The struggle that he went through in setting up a private health care facility in the India of the 1980s is part of folklore
We aim to test 500,000 patients a day in 5 years: Dr Lal PathLabs CMD

9.25 pm | 18 May 2022 | Business Standard

Dr Lal PathLabs is India's largest diagnostic services player by revenue, with 289 laboratories across the country
Caring for patients runs in our DNA, say Cipla's Samina Hamied, Umang Vohra

9.22 pm | 18 May 2022 | Business Standard

'Cipla has so many capabilities that for anything we need to do, we say we can do it'
Rejuvenating Cipla: After global expansion, acquisitions on cards

9.18 pm | 18 May 2022 | Business Standard

Having consolidated its presence across geographies, the pharma major is looking at acquisitions
Dr Reddy's Q4 PAT may rise 28% YoY; margins likely to fall, say analysts

3.16 pm | 18 May 2022 | Business Standard

The pharmaceutical giant may witness some impact due to its large exposure of the business to Russia, and CIS regions.
Dr Lal Pathlabs slips 6%, hits 52-week low post muted Q4 results

9.52 am | 18 May 2022 | Business Standard

In Q4FY22, normalised earnings before interest, taxes, depreciation, and amortization (EBITDA) margins contracted 630 bps to 19.4 per cent from 25.7 p...
Dr Lal Pathlabs Q4 consolidated PAT dips 27% to Rs 62 cr, stock sheds 1%

1.47 am | 18 May 2022 | Business Standard

Operating revenue rose 12.7% during the quarter to Rs 485.5 cr; Covid-19 and allied segments added roughly 13.6% to Q4 top line
Aurobindo hits 2-year low; dips 11% in a week on USFDA's 6 observations

12.42 pm | 17 May 2022 | Business Standard

Analysts at ICICI Securities expect Aurobindo Pharma's adjusted PAT to de-grow 30.4 per cent year-on-year (YoY) to Rs 557.90 crore in the March 2022 q...
GlaxoSmithKline Pharma reports consolidated net loss of Rs 55 crore

1.05 am | 17 May 2022 | Press Trust of India

Revenue from operations rose to Rs 810 crore for the fourth quarter, compared with Rs 744 crore in the year-ago period, the pharmaceutical major said ...
USFDA rush after 2-year lull: 20-30% new products may be open to inspection

3.01 am | 16 May 2022 | Business Standard

The last two years saw limited physical inspections due to travel restrictions during the pandemic
A first in India: Zydus brings new drug for uncontrolled 'bad' cholesterol

12.04 am | 14 May 2022 | Business Standard

Uncontrolled LDL-c, which poses a major risk of cardiovascular diseases, lacked proper treatment despite patients' lifestyle changes and use of statin...
Cipla looks to invest more in mRNA tech; holds discussions with firms

2.03 am | 12 May 2022 | Business Standard

Speaking to Business Standard, Samina Hamied, executive vice chairperson, Cipla, says one must invest in research and development (R&D) to feed the co...
Cipla will use Covid-19 bulk drugs inventory when demand rises

11.46 pm | 11 May 2022 | Business Standard

The Covid-19 portfolio contributed 5-6 per cent of Cipla's turnover during peak Covid waves, the firm said
Bonus issue fails to lift Ajanta Pharma; stock hits 52-week low on weak Q4

12.27 pm | 11 May 2022 | Business Standard

In Q4FY22, Ajanta's earnings before interest, taxes, depreciation, and amortization declined 20 per cent year-on- year to Rs 207 crore.
Stocks to Watch: SBI, Cipla, Voda Idea, Gujarat Gas, Zensar, MGL, Welspun

8.11 am | 11 May 2022 | Business Standard

Stocks to Watch Today: The primary market too is likely to be abuzz with activity with three IPOs namely - Delhivery, Prudent Corporate Advisory Servi...
Cipla Q4 PAT dips 12% to Rs 362 cr owing to Covid inventory impact

2.26 am | 11 May 2022 | Business Standard

For the full fiscal, Cipla has posted a 4.7% jump in net profit to Rs 2,517 crore, revenue and Ebitda rose 13.6% and 6.4% respectively
Sun Pharma's Halol unit gets 10 observations under USFDA's Form 483

1.22 am | 11 May 2022 | Business Standard

Plant's OAI status is unchanged, hinting at status quo; Sun Pharma says will respond to observations within 15 days
Rainbow Medicare slumps 17% on debut in worst IPO listing in CY22 so far

11.10 pm | 10 May 2022 | Business Standard

Stock end at Rs 450, Rs 92 below issue price of Rs 542 a share
Rainbow Children's Medicare lists at 7% discount to issue price

10.30 am | 10 May 2022 | Business Standard

The stock listed at Rs 506, a 7% discount when compared with its issue price of Rs 542 per share on the BSE.